DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Toxoplasmosis, Cerebral; HIV Infections

Intervention: Pyrimethamine (Drug); Clindamycin (Drug)

Phase: N/A

Status: Completed

Sponsored by: Palo Alto Medical Foundation

Summary

To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Clinical Details

Official title: Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded:

- Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal

meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy. Patients with other opportunistic infections or brain diseases are excluded. Patients with AIDS and cerebral toxoplasmosis.

Locations and Contacts

Palo Alto Med Foundation, Palo Alto, California 94301, United States
Additional Information


Last updated: June 23, 2005

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017